Search results for: Margherita Neri
Filter search results
The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision
8 October 2020
…Brassel, S., Neri, M., O’Neill, P., and Steuten L., 2020a. Realising the value of vaccines in the UK. OHE Consulting Report, London: Office of Health Economics. Available at: https://www.ohe.org/publications/realising-broader-value-vaccines-uk Retrieved…
Payment Models for Multi-Indication Therapies
1 November 2021
…systems must be utilised and evolve to accommodate this need, in order to realise full benefits of medical innovation for patients and health systems. Citation Cole, A., Neri, M. and…
Improving the Measurement of Valued Output in Primary Care in England
1 August 2022
…linked to this blog post when it is publicly available. Related research Neri, M., Cubi-Molla, P. & Cookson, G. Approaches to Measure Efficiency in Primary Care: A Systematic Literature Review….
The World Needs New Antibiotics. A Proposed US Program to Develop Them Offers a High Pay-Off
16 November 2022
…al. A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance. Appl Health Econ Health Policy 18, 69–79 (2020). https://doi.org/10.1007/s40258-019-00516-0 Neri, M., Hampson, G., Henshall, C….
The BRAVE Initiative: The BRAVE Narrative for Broad Recognition of Value in Vaccines Engagement
1 September 2020
…these gaps. Please note, this report has been superseded by the following journal publication: Bell, E., Neri, M., & Steuten, L. (2021). Towards a Broader Assessment of Value in Vaccines:…
Reforming Primary Health Care in Middle-Income Countries: The Good, the Bad, and the Ugly
18 July 2022
…Paper 1520, Economic Research Forum (ERF), Cairo. Link. Neri, M., Cubi-Molla, P. and Cookson, G., 2022. Approaches to Measure Efficiency in Primary Care: a Systematic Literature Review. Applied Health Economics…
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
…Novel Diagnostics to Manage Antimicrobial Resistance. Appl Health Econ Health Policy 18, 69–79 (2020). https://doi.org/10.1007/s40258-019-00516-0 Neri, M., Hampson, G., Henshall, C. and Towse, A., 2019. HTA and payment mechanisms for…
New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
25 May 2023
…for Global Development | Ideas to Action (cgdev.org) Neri, M., Hampson, G., Henshall, C. and Towse, A. 2019. HTA and Payment Mechanisms for New Drugs to Tackle AMR. OHE Grant-Funded…
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
…Health Care. 2021;37(S1):19-19. doi:10.1017/S0266462321001124 Berdud M, Drummond M, Towse A. Establishing a reasonable price for an orphan drug. Cost Eff Resour Alloc. 2020;18(1):31. doi:10.1186/s12962-020-00223-x Cole A, Neri M, Cookson G….